Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Shenzhen Stock Exchange 300204.SZ

Staidson (Beijing) BioPharmaceuticals Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2023: -271.27

Staidson (Beijing) BioPharmaceuticals Co., Ltd. Interest Coverage Ratio is -271.27 for the year ending December 31, 2023, a 60.01% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Staidson (Beijing) BioPharmaceuticals Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2022 was -678.38, a -108.26% change year over year.
  • Staidson (Beijing) BioPharmaceuticals Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2021 was -325.74, a -109.64% change year over year.
  • Staidson (Beijing) BioPharmaceuticals Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2020 was -155.38, a -838.77% change year over year.
  • Staidson (Beijing) BioPharmaceuticals Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2019 was 21.03, a -84.73% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
Shenzhen Stock Exchange: 300204.SZ

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

CEO Mr. Wang Chao
IPO Date April 15, 2011
Location China
Headquarters No. 36, Jinghai Er Road
Employees 555
Sector Health Care
Industries
Description

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

StockViz Staff

January 16, 2025

Any question? Send us an email